⚠️ Research Use Only. AOD-9604 10mg is supplied strictly for in-vitro laboratory research purposes only. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All content below reflects peer-reviewed preclinical and published scientific literature only. This content is not medical advice.
If your laboratory research programme has moved beyond preliminary investigation into AOD-9604 and requires a compound volume that supports full dose-response protocols, multi-arm experimental designs, and extended studies from one vial, the AOD-9604 10mg research peptide is the appropriate format for your next phase of work.
The AOD-9604 10mg research peptide is the advanced-format version of a widely studied lipolysis research compound in the UK metabolic research peptide category. Its scientific profile (lipolytic activity in preclinical models, with no change in serum IGF-1 reported in human trials) is the same in both formats. What changes at 10mg is research capacity: the ability to run full concentration gradients, parallel experimental arms, and extended single-batch studies from one vial.
This guide is written specifically for UK-based researchers who are already familiar with AOD-9604 at the 5mg level and are evaluating the 10mg format for an established programme. For a complete introduction to AOD-9604 science, mechanism, and first-time research considerations, see our dedicated AOD-9604 5mg research peptide guide. All content relates strictly to laboratory research. The AOD-9604 10mg research peptide is supplied by Ascend Peptides UK for in-vitro research use only, not for human consumption, veterinary, or clinical application.
What is the AOD-9604 10mg Research Peptide?
AOD-9604 is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH) — specifically, residues 177 through 191 with an added N-terminal tyrosine. The “AOD” designation stands for Anti-Obesity Drug, reflecting the original research objective when the compound was developed from research at Monash University in Australia and later by Metabolic Pharmaceuticals. That N-terminal tyrosine is why the compound is also described in the literature as Tyr-hGH(177-191).
The AOD-9604 10mg research peptide is the same compound as the 5mg format. It has been studied for lipolytic activity (the breakdown of stored triglycerides), mainly in adipose tissue from obese rodents (Ng et al., 2000; Heffernan et al., 2001). It is not reported to act through the growth hormone receptor (GHR), and in placebo-controlled human trials it did not change serum IGF-1 or impair glucose tolerance (Stier et al., 2013). For metabolic study design, this means GH-receptor-driven IGF-1 elevation is not expected as a confounding variable.
AOD-9604 10mg Research Peptide — Molecular Identity
|
Identifier |
Value |
|---|---|
|
Scientific name |
AOD-9604 (Anti-Obesity Drug 9604) |
|
Alternative names |
Tyr-hGH(177-191); not the same peptide as native hGH fragment 176-191 |
|
Type |
Synthetic hexadecapeptide (16 amino acids) |
|
Sequence |
YLRIVQCRSVEGSCGF (disulphide bond Cys-7 to Cys-14) |
|
N-terminal modification |
Tyrosine (Tyr) residue added at the N-terminus |
|
Molecular formula |
C78H123N23O23S2 |
|
Molecular weight |
~1,815.1 g/mol (reference value, PubChem CID 71300630) |
|
Origin |
Residues 177–191 of human growth hormone (hGH) with an added N-terminal tyrosine |
|
Primary mechanism |
Lipolytic activity in adipose tissue from obese rodents; mechanism not established |
|
IGF-1 independence |
No change in serum IGF-1 in placebo-controlled human trials (Stier et al., 2013) |
|
GHR binding |
Not reported to act through the growth hormone receptor (GHR) |
|
Research category |
Metabolic Research Peptide |
|
Format (10mg) |
Lyophilised powder — white to off-white |
|
Testing standard |
No Janoshik certificate is currently published for AOD-9604 |
Why Choose AOD-9604 10mg for Research? The Case for the Advanced Format
The decision between AOD-9604 5mg and AOD-9604 10mg is not about which compound is superior; the molecular structure is identical, and no Certificate of Analysis is currently published for either format. The decision is about which format is appropriate for the scale and design of your research programme.
The 10mg format becomes the correct choice when your experimental design requires one or more of the following: a full dose-response concentration gradient across multiple wells or treatment groups; parallel experimental arms comparing AOD-9604 with other metabolic research compounds; longitudinal studies requiring consistent compound conditions across multiple time points from a single batch; or high-throughput assay designs that need more material from one vial.
|
Research Consideration |
AOD-9604 5mg |
AOD-9604 10mg |
|---|---|---|
|
Best suited for |
Pilot studies, method validation, preliminary investigations |
Established programmes, multi-arm studies, full dose-response |
|
Research stage |
First-time AOD-9604 research, assay development |
Confirmed research design, ongoing programme |
|
Dose-response range |
Limited concentration gradient |
Full dose-response curve capability |
|
Number of aliquots |
Fewer single-use aliquots per vial |
Greater aliquot volume — fewer batch changes |
|
Batch consistency |
Single-batch for focused pilot series |
More material from one vial for extended series |
|
Multi-arm protocols |
Single-compound arms only |
Supports parallel compound arms simultaneously |
|
Cost efficiency |
Higher per mg — appropriate for pilot stage |
Better value for active research programmes |
|
Institutional suitability |
CRO pilots, academic method development |
Institutions, established CROs, multi-researcher labs |
|
Purity standard |
No Janoshik certificate published yet |
No Janoshik certificate published yet |
For researchers beginning their first investigation with this compound and validating assay conditions before committing to a full programme, the AOD-9604 5mg research peptide guide covers the pilot-stage format in detail.
Mechanism of Action: How AOD-9604 10mg Works in Laboratory Research Models
Understanding the mechanism of the AOD-9604 10mg research peptide at a molecular level is essential for designing valid experimental protocols and correctly attributing observed outcomes to the compound’s specific activity. Three mechanistic properties define how AOD-9604 behaves in research models.
1. Beta-3 Adrenergic Receptor (β3-AR) Research Findings
Published research on AOD-9604 has examined the beta-3 adrenergic receptor (β3-AR), a G-protein-coupled receptor expressed predominantly in adipose tissue.[2] In obese mice, chronic AOD-9604 treatment increased β3-AR mRNA levels; in β3-AR knock-out mice, chronic treatment did not produce the weight loss or increased lipolysis seen in wild-type animals, although a single acute dose still increased energy expenditure and fat oxidation. The authors concluded that its lipolytic actions are not mediated directly through the β3-AR, while increased β3-AR expression may contribute to lipolytic sensitivity. The precise mechanism has not been established.
Lipolysis releases free fatty acids and glycerol, which are the usual readouts in lipolysis assays.
2. IGF-1 Independence — The Key Research Advantage
Unlike full-length hGH, AOD-9604 is not reported to act through the growth hormone receptor (GHR), and in six placebo-controlled human trials it did not change serum IGF-1 (Stier et al., 2013). For experimental design, this is the property that most distinguishes it from full-length hGH.
Research models using full-length hGH must account for IGF-1 elevation as a confounding variable that independently affects cell proliferation, glucose metabolism, and anabolic signalling. AOD-9604 is not expected to introduce GH-receptor-driven IGF-1 elevation, although other systemic effects in whole-animal models still need appropriate controls.
3. Lipogenesis: Related-Fragment Data Only
Reduced lipogenesis (new triglyceride synthesis) was reported for AOD9401, the closely related fragment hGH 177-191 without the added tyrosine, in obese mice and in rodent and human adipose tissue (Heffernan et al., 2000). The AOD-9604 sources reviewed for this guide do not report lipogenesis data, so this finding should not be assumed for AOD-9604.
How lipolytic and lipogenic effects relate mechanistically has not been established.
The 10mg format provides more material from one vial for concentration-response work on both measures.
AOD-9604 10mg vs HGH Fragment 176-191 vs Full-Length hGH
Researchers evaluating the AOD 9604 10mg research compound against related metabolic research tools need clarity on exactly how these compounds differ at the molecular level. The following comparison provides the key distinctions relevant to experimental design.
|
Property |
AOD-9604 10mg |
HGH Fragment 176-191 |
Full-Length hGH |
|---|---|---|---|
|
Amino acids |
16 (+ Tyr N-terminal) |
16 (unmodified) |
191 (full protein) |
|
Molecular weight |
~1,815.1 g/mol (reference) |
~1,799 Da (native sequence starts with Phe) |
~22,000 Da |
|
N-terminal Tyr |
✓ Added (N-terminal tyrosine) |
✗ No modification |
✗ Not applicable |
|
GHR binding |
Not reported to act via GHR |
Not established in the sources reviewed |
✓ Primary GHR agonist |
|
IGF-1 stimulation |
No serum IGF-1 change in human trials |
Not established in the sources reviewed |
✓ Strong IGF-1 release |
|
Lipolysis |
Reported in obese rodent models |
Not established for this exact sequence |
Established |
|
Anabolic effects |
✗ Not documented |
✗ Not documented |
✓✓ Muscle + bone growth |
|
Glucose effect |
No adverse effect on glucose tolerance in human trials |
Not established; hyperglycaemic action has been reported for synthetic hGH C-terminal fragments (ref. 1) |
✓✓ Can cause hyperglycaemia |
|
Research advantage |
Modified (tyrosine added at the N-terminus) |
Native fragment |
Broad multi-pathway tool |
|
Research category |
Metabolic Research |
Metabolic Research |
Growth Hormone Research |
The practical implication for the AOD 9604 10mg research format specifically: when designing multi-compound metabolic studies that require concurrent investigation of lipolytic mechanisms and growth factor signalling, AOD-9604 and full-length hGH provide complementary research probes.
AOD-9604 is studied for lipolytic activity without IGF-1 elevation; full-length hGH engages the GHR/IGF-1/anabolic pathway simultaneously. Comparing the two in parallel arms of the same protocol allows their pathway effects to be contrasted.
Research Applications of AOD-9604 10mg in UK Laboratory Settings
The AOD-9604 10mg research peptide is used across a range of scientific disciplines within the Metabolic Research Peptide category. The following research contexts represent the primary applications documented in published preclinical literature, with specific considerations for the 10mg format.
|
Research Area |
AOD-9604 Role |
Format Recommendation |
|---|---|---|
|
Adipocyte lipolysis research |
Primary tool — lipolysis research in fat cell models |
5mg for pilot / 10mg for full dose-response |
|
Lipogenesis studies |
Reported for the related fragment AOD9401 only; AOD-9604 data not found |
10mg — multiple concentration arms needed |
|
Metabolic pathway studies |
IGF-1 independent metabolic signalling investigation |
10mg — extended single-batch for longitudinal studies |
|
AOD vs hGH fragment comparison |
Side-by-side lipolytic mechanism comparison |
10mg — dual compound protocols |
|
Cartilage and joint cell research |
One rabbit osteoarthritis study (Ann Clin Lab Sci, 2015) |
5mg for initial investigation |
|
Bone metabolism research |
No published AOD-9604 bone data found |
5mg for pilot / 10mg for established study |
|
Beta-3 adrenergic receptor expression studies |
Beta-3 AR expression studies in receptor biology |
10mg — expression time-course studies |
|
Obesity model cell studies |
Obese rodent models are the main published system |
10mg — critical for comparative study design |
For researchers whose metabolic study programme also involves growth factor signalling alongside lipolysis research, our IGF-1 LR3 1mg research guide covers IGF-1 LR3, a growth factor analogue that acts through the IGF-1 receptor pathway rather than the lipolytic pathways studied with AOD-9604.
For growth hormone axis research that requires upstream GHRH pathway stimulation alongside metabolic compound investigation, our tesamorelin 10mg research guide and CJC-1295 Without DAC research guide cover the GHRH analogue research compounds — mechanistically distinct from AOD-9604 and frequently studied in parallel in comprehensive metabolic research programmes.
Where to Buy AOD-9604 10mg Research Peptide UK
When sourcing the AOD-9604 10mg research peptide in the UK, the quality and analytical verification of the compound are directly linked to the reliability of your experimental data.
A 16-amino acid hexadecapeptide with an N-terminal tyrosine modification requires rigorous analytical confirmation; both purity and structural identity must be independently verified before use in any serious laboratory programme.
These are the quality standards to look for from any UK AOD-9604 10mg supplier, including Ascend Peptides UK. Ascend’s current Janoshik certificates state measured content and purity for each tested batch; identity methods such as LC-MS are not separately reported on them:
-
HPLC purity verification: a purity figure measured by High-Performance Liquid Chromatography on a batch-specific certificate from an independent analytical laboratory (there is no single legal purity standard)
-
LC-MS molecular identity confirmation: Molecular weight verified to match expected AOD-9604 structure (C78H123N23O23S2, MW ~1,815.1 g/mol), including confirmation that the N-terminal tyrosine modification is intact
-
Independent third-party testing: testing by a specialist external analytical laboratory, not in-house
-
Lyophilised powder format: Research peptides are usually supplied freeze-dried; storage conditions should come from the manufacturer specification
-
Full batch traceability: Complete documentation for publication referencing and institutional compliance reporting
-
Research-only labelling: No health, cosmetic, or clinical claims, clear metabolic research peptide UK designation
-
UK-based dispatch: Same working-day dispatch for orders placed before 3 pm, no international transit delays or stability risks
Buy AOD-9604 10mg research peptide directly from Ascend Peptides UK, or explore our complete range of metabolic research peptides and scientific compounds, all dispatched the same working day for orders before 3 pm, with free shipping on orders of £50 or more.
UK Regulatory Status and Research Compliance
The AOD-9604 10mg research peptide is classified as a research chemical in the United Kingdom. It is not a licensed medicine, not approved for human consumption, and must not be used in any clinical, therapeutic, veterinary, or diagnostic context outside of properly regulated research frameworks. It is not classified as a controlled substance under UK law.
Researchers should note that AOD-9604 completed Phase II clinical trials under the pharmaceutical development programme of Metabolic Pharmaceuticals before the programme was discontinued.
A peer-reviewed summary of six placebo-controlled trials reports safety and tolerability, no change in serum IGF-1 and no adverse effect on glucose tolerance, but does not report weight-loss efficacy (Stier et al., 2013). However, this clinical history does not extend any licensed status to the 10mg lyophilised research format, which is supplied strictly for laboratory investigation only.
AOD-9604 is listed on the World Anti-Doping Agency (WADA) Prohibited List and is subject to UK Anti-Doping (UKAD) regulations. Athletes subject to anti-doping regulations must not use this compound.
Sports-science researchers should note this listing.
For any in-vivo animal research conducted in the United Kingdom, full compliance with the Animals (Scientific Procedures) Act 1986 (ASPA) is mandatory, requiring valid Home Office licences and institutional ethical approval.
Why UK Researchers Choose Ascend Peptides UK for AOD-9604 10mg
-
Testing status: No Janoshik certificate is currently published for AOD-9604; published certificates for other products are listed on the CoA page
-
Both formats available: AOD-9604 5mg for pilot work; AOD-9604 10mg for established programmes, allowing seamless format progression without supplier change
-
UK-based supplier: Same working-day dispatch for orders before 3 pm, no international transit delays
-
Free shipping: On all orders of £50 or more across the United Kingdom
-
Complete metabolic research range: AOD-9604 available alongside IGF-1 LR3, tesamorelin, CJC-1295 and ipamorelin; the CoA page shows which products have a published certificate
-
Research-only supply: No health, cosmetic, or clinical claims on any product
Frequently Asked Questions AOD-9604 10mg Research Peptide UK
Q: What is the AOD-9604 10mg research peptide?
A: A synthetic 16-amino acid peptide derived from the C-terminal fragment of human growth hormone (Tyr-hGH(177-191): residues 177-191 with an added N-terminal tyrosine). It has been studied for lipolytic activity in obese rodent models; it is not reported to act through the growth hormone receptor and did not change serum IGF-1 in human trials. Published research concluded that its lipolytic actions are not mediated directly through the beta-3 adrenergic receptor. For laboratory research use only.
Q: What is the difference between AOD-9604 5mg and 10mg?
A: The compound is identical; only the quantity differs. The 5mg format suits pilot studies and method validation. The 10mg format is for established programmes requiring full dose-response gradients, multi-arm designs, and larger quantities for longitudinal designs.
Q: What is the difference between AOD-9604 and HGH Fragment 176-191?
A: Both are 16-residue peptides that share hGH residues 177-191. The native hGH 176-191 sequence starts with phenylalanine (hGH residue 176; UniProt P01241), whereas AOD-9604 starts with an added tyrosine, so it is described as Tyr-hGH(177-191). Products sold as “HGH Fragment 176-191” do not always state which sequence they contain, so check the sequence given. The mechanism of AOD-9604’s lipolytic action has not been established.
Q: Does AOD-9604 10mg stimulate IGF-1?
A: In six placebo-controlled human trials, AOD-9604 did not change serum IGF-1 (Stier et al., 2013), and it is not reported to act through the growth hormone receptor (GHR), the receptor that drives IGF-1 release. Whole-animal studies still need appropriate controls.
Q: Has AOD-9604 been studied in humans?
A: Yes. Six randomised, placebo-controlled trials (phases I to IIb) were run during its development as an anti-obesity drug. The peer-reviewed summary reports a safety and tolerability profile similar to placebo, no change in serum IGF-1, no adverse effect on glucose tolerance and no anti-AOD-9604 antibodies (Stier et al., 2013). It does not report weight-loss efficacy, and AOD-9604 was not approved as a medicine. These trials do not verify any research-supply batch.
Q: Is AOD-9604 10mg legal in the UK?
A: Yes legal to purchase as a research chemical for laboratory use. It is not a controlled substance under UK law. However, AOD-9604 is listed on the WADA Prohibited List and must not be used by athletes. For research use only.
Q: What purity standard should AOD-9604 10mg meet?
A: An HPLC purity figure on a batch-specific certificate (there is no single legal purity standard), with LC-MS molecular identity confirmation (C78H123N23O23S2, ~1,815.1 g/mol). A batch-specific Certificate of Analysis from an independent third-party laboratory is essential. No Janoshik certificate is currently published for AOD-9604.
Q: Where can I buy AOD-9604 10mg in the UK?
A: Directly from Ascend Peptides UK, same working-day dispatch before 3 pm, free shipping on orders of £50 or more. No Janoshik certificate is currently published for AOD-9604. For laboratory research use only.
Q: Can AOD-9604 10mg be used in multi-compound protocols?
A: Yes. AOD-9604 has been studied for lipolytic activity independent of the IGF-1 axis and GHRH pathway, so its effects can be compared with those of IGF-1 LR3 or GHRH analogues such as CJC-1295 and tesamorelin. In whole-animal designs, GHRH analogues raise GH and IGF-1, so these compounds are not independent variables and need appropriate controls.
Conclusion: AOD-9604 10mg Research Peptide UK
The AOD-9604 10mg research peptide is a metabolic research peptide with a defined but limited evidence base. Its lipolytic activity in obese rodent models, together with the absence of an IGF-1 change in human trials, makes it a useful tool for studying fat-metabolism pathways without GH-receptor-driven IGF-1 elevation.
At the 10mg format, this precision is delivered with the research capacity required for full dose-response protocols, multi-arm experimental designs, and the larger quantity per vial that longitudinal designs may need.
For UK researchers and laboratories sourcing the AOD-9604 10mg research peptide from a reliable UK supplier, Ascend Peptides UK supplies this compound with same working-day UK dispatch on in-stock orders; no Janoshik certificate is currently published for AOD-9604.
Buy AOD-9604 10mg research peptide today from Ascend Peptides UK.
Scientific References
1. Ng FM, Bornstein J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 234(5): E521-6. PMID: 645904
2. Heffernan MA, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 142(12):5182-9. PMID: 11713213
3. Ng FM, et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 53(6):274-8. PMID: 11146367
4. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 279(3):E501-7. PMID: 10950816 (studies AOD9401, hGH 177-191, not AOD-9604)
5. Stier H, Vos E, Kenley D. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 3(1-2):7-15.
6. (2015). Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 45(4):426-32. PMID: 26275694
Molecular data: PubChem CID 71300630 (AOD-9604).
DISCLAIMER
All products supplied by Ascend Peptides UK are intended strictly for research purposes only. They are not intended for human consumption or for any therapeutic, diagnostic, or clinical use. None of the items offered are classified as medicinal products by the MHRA and must not be marketed, presented, or used as such. It is the buyer’s responsibility to ensure that all purchases and usage comply with applicable laws and regulations. Ascend Peptides UK accepts no liability for misuse of products or for any resulting consequences.

